CMO和CDMO生物技術市場規模、佔有率和成長分析：按服務類型、分子類型、最終用戶、規模、服務模式和地區分類——產業預測，2026-2033年

2024 年全球 CMO 和 CDMO 生物技術市場價值為 186.4 億美元，預計到 2025 年將成長至 203.5 億美元，到 2033 年將成長至 411.6 億美元，在預測期（2026-2033 年）內複合年成長率為 9.2%。

契約製造組織 (CMO) 和合約開發與生產組織 (CDMO) 在支持缺乏自有生產能力的生物技術公司方面發揮著至關重要的作用，這主要得益於生技藥品核准速度的快速成長。尤其是在個人化醫療需求加速成長的背景下，企業擴大將複雜的生產流程外包，這需要靈活的設施和先進的資料整合平台。這種轉變正在推動對模組化設施的大量投資，加速產能成長和多元化。此外，人工智慧驅動的自動化正在透過簡化工作流程並將數據驅動模型與機器人執行相結合，徹底改變整個產業，從而提高生產一致性並縮短週期時間。數位孿生和自適應流體處理系統的應用確保了對不斷變化的治療需求的敏捷響應，最終加快監管申報速度，並為申辦方提供更具吸引力的服務。

全球CMO和CDMO生物技術市場的成長要素

隨著企業擴大將複雜生技藥品的研發外包給專業合作夥伴，全球CMO和CDMO生物技術市場正經歷顯著成長。這種策略使生物製藥公司能夠利用外部生產專長，同時專注於核心創新，從而加快產品平臺並擴大市場進入。合約服務模式提供了快速擴大生產規模所需的柔軟性，這對於滿足日益成長的患者需求和增強對外包解決方案的信心至關重要。這種協作方式不僅縮短了研發週期，也促進了生物技術領域中各個治療領域的持續拓展。

全球CMO和CDMO生物技術市場的限制因素

生物技術外包產業面臨複雜的監管挑戰，且各地區差異顯著，導致契約製造製造商需要提交大量文件並進行驗證。這些地區差異要求具備專業知識才能應對不同的法規結構，這可能會延長核准時間，並為服務供應商及其客戶帶來營運上的不確定性。因此，企業在關鍵流程中可能不願意與外部公司合作，而是選擇依賴內部資源來管理合規風險。這種趨勢最終會阻礙市場成長，並限制新型生技藥品快速進入全球醫療保健系統。

全球CMO和CDMO生物技術市場趨勢

在全球生物技術合約生產組織（CMO）和合約研發生產組織（CDMO）市場中，受個人化醫療領域快速發展的推動，市場呈現出強勁的成長動能。基因組學和先進數據分析的協同效應促使契約製造公司不斷提升自身能力，開發滿足患者個別需求的客製化生技藥品。隨著生物製藥公司日益尋求在基因編輯、細胞培養最佳化和適應性生產方面經驗豐富的合作夥伴，對模組化和柔軟性設施的需求也隨之成長。這一趨勢使得合約生產服務商扮演著至關重要的推動者角色，他們能夠簡化從藥物發現到臨床供應的整個流程，同時應對全球各地不同的法規環境和市場細分。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球CMO和CDMO生物技術市場規模：按服務類型分類

• 藥物研發
• 製程開發
• 製造業
• 分析測試

全球CMO與CDMO生物技術市場規模：依分子類型分類

• 單株抗體
• 重組蛋白
• 細胞和基因治療
• 疫苗

全球CMO和CDMO生物技術市場規模：依最終用戶分類

• 生技公司
• 製藥公司
• 研究機構

全球CMO和CDMO生物技術市場規模：依規模

• 臨床前階段
• 臨床階段
• 商業的

全球CMO與CDMO生物技術市場規模：依服務模式分類

• CMO
• CDMO

全球CMO和CDMO生物技術市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Lonza Group AG
• Catalent, Inc.
• Samsung Biologics Co., Ltd.
• FUJIFILM Diosynth Biotechnologies
• WuXi Biologics（Cayman）Inc.
• Thermo Fisher Scientific Inc.
• AGC Biologics
• Boehringer Ingelheim International GmbH
• Recipharm AB
• Bachem Holding AG
• CordenPharma International GmbH
• Rentschler Biopharma SE
• KBI Biopharma, Inc.
• PCI Pharma Services
• Almac Group
• MilliporeSigma
• Curia Global, Inc.
• BSP Pharmaceuticals SpA
• Oxford Biomedica plc
• Celltrion Inc.

結論與建議

Global Cmo And Cdmo Biotechnology Market size was valued at USD 18.64 Billion in 2024 and is poised to grow from USD 20.35 Billion in 2025 to USD 41.16 Billion by 2033, growing at a CAGR of 9.2% during the forecast period (2026-2033).

The contract manufacturing organization (CMO) and contract development and manufacturing organization (CDMO) sector plays a pivotal role in supporting biotech firms lacking in-house production capabilities, fueled by the surging approval rates for biologics. As demand accelerates, particularly for personalized medicines, companies increasingly outsource intricate manufacturing processes, necessitating flexible equipment and advanced data-integration platforms. This shift has prompted substantial investment in modular facilities, enhancing capacity and promoting diversification. Moreover, AI-powered automation is revolutionizing this landscape by streamlining workflows, linking data-driven models with robotic execution for improved consistency and reduced cycle times. The use of digital twins and adaptive liquid-handling systems ensures an agile response to evolving therapeutic needs, ultimately facilitating quicker regulatory submissions and enhancing service appeal for sponsors.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cmo And Cdmo Biotechnology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cmo And Cdmo Biotechnology Market Segments Analysis

Global cmo and cdmo biotechnology market is segmented by service type, molecule type, end user, scale, service model and region. Based on service type, the market is segmented into Drug Development, Process Development, Manufacturing and Analytical Testing. Based on molecule type, the market is segmented into Monoclonal Antibodies, Recombinant Proteins, Cell & Gene Therapies and Vaccines. Based on end user, the market is segmented into Biotechnology Companies, Pharmaceutical Companies and Research Organizations. Based on scale, the market is segmented into Preclinical, Clinical and Commercial. Based on service model, the market is segmented into CMO and CDMO. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cmo And Cdmo Biotechnology Market

The global CMO and CDMO biotechnology market is experiencing significant growth as companies increasingly outsource complex biologic development to specialized partners. This strategy allows biopharma firms to streamline their focus on core innovations while utilizing external manufacturing expertise, thus expediting product pipelines and broadening market access. The contract services model provides the flexibility needed for rapid scaling of production volumes, which is essential in meeting the rising demands of patients and enhancing trust in outsourced solutions. This collaborative approach not only accelerates development timelines but also fosters continued expansion within various therapeutic areas in the biotechnology sector.

Restraints in the Global Cmo And Cdmo Biotechnology Market

The biotechnology outsourcing sector encounters complex regulatory challenges that vary significantly across different regions, leading to extensive documentation and validation requirements for contract manufacturers. This variability necessitates specialized knowledge to navigate the disparate regulatory frameworks, potentially lengthening approval timelines and introducing operational unpredictability for both service providers and their clients. As a result, companies may be reluctant to partner with external entities for essential processes, opting instead to rely on in-house capabilities to manage compliance risks. This tendency ultimately hampers market growth and restricts the rapid introduction of new biologic products into global healthcare systems.

Market Trends of the Global Cmo And Cdmo Biotechnology Market

The Global CMO and CDMO Biotechnology market is experiencing significant momentum driven by the burgeoning field of personalized therapeutics. The interplay of genomics and sophisticated data analytics is prompting contract manufacturing organizations to hone their capabilities in developing bespoke biologics tailored to individual patient needs. As biopharmaceutical companies increasingly seek partners adept in gene editing, cell-culture optimization, and adaptive manufacturing, the demand for modular and flexible facilities is on the rise. This trend positions contract providers as vital catalysts, streamlining the path from discovery to clinical supply and catering to a diverse range of regulatory environments and market segments worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global CMO and CDMO Biotechnology Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Drug Development
• Process Development
• Manufacturing
• Analytical Testing

Global CMO and CDMO Biotechnology Market Size by Molecule Type & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibodies
• Recombinant Proteins
• Cell & Gene Therapies
• Vaccines

Global CMO and CDMO Biotechnology Market Size by End User & CAGR (2026-2033)

• Market Overview
• Biotechnology Companies
• Pharmaceutical Companies
• Research Organizations

Global CMO and CDMO Biotechnology Market Size by Scale & CAGR (2026-2033)

• Market Overview
• Preclinical
• Clinical
• Commercial

Global CMO and CDMO Biotechnology Market Size by Service Model & CAGR (2026-2033)

• Market Overview
• CMO
• CDMO

Global CMO and CDMO Biotechnology Market Size & CAGR (2026-2033)

• North America (Service Type, Molecule Type, End User, Scale, Service Model)
  • US
  • Canada
• Europe (Service Type, Molecule Type, End User, Scale, Service Model)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Service Type, Molecule Type, End User, Scale, Service Model)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Service Type, Molecule Type, End User, Scale, Service Model)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Service Type, Molecule Type, End User, Scale, Service Model)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Lonza Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Biologics Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Diosynth Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (Cayman) Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AGC Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recipharm AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bachem Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CordenPharma International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rentschler Biopharma SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KBI Biopharma, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PCI Pharma Services
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MilliporeSigma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BSP Pharmaceuticals S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Biomedica plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celltrion Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations